ArticleBritish journal of cancer2018

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis.

Katsunori Tatsugami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.